AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioArctic gains 7.5% after Novartis collaboration deal
ByAinvest
Tuesday, Aug 26, 2025 3:01 am ET1min read
BioArctic gains 7.5% after Novartis collaboration deal
Stockholm, Sweden — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) experienced a 7.5% increase in its stock price following the announcement of a significant collaboration and licensing agreement with Novartis Pharma AG. The agreement, announced on August 26, 2025, involves the use of BioArctic's proprietary BrainTransporter technology in a potential new treatment for neurodegeneration [1].As part of the initial research collaboration, BioArctic will receive an upfront payment of USD 30 million. If Novartis decides to exercise their option to license any drug candidate generated, BioArctic could receive additional payments of up to USD 772 million. Additionally, BioArctic will be entitled to tiered mid-single digit royalties on future global product sales if the product reaches the market [1].
The agreement is the third collaboration BioArctic has entered into with partners using the BrainTransporter technology. This versatile platform has the potential to improve many different projects, both internally and externally generated, and could support companies across the field in their pursuit of helping people with brain disorders [1].
The BrainTransporter technology facilitates the passage of biological drugs into the brain using the transferrin receptor (TfR). This can result in broader brain distribution, enabling better efficacy, improved safety profile, and dosing convenience. The technology is being applied to several in-house drug projects and could become part of future collaborations with other pharmaceutical companies [1].
The collaboration between BioArctic and Novartis underscores the potential of the BrainTransporter technology to advance the development of innovative therapies for severe neurological conditions. This agreement is part of BioArctic's broader research portfolio, which includes projects against Alzheimer's disease, Parkinson's disease, and ALS [1].
References:
[1] https://www.morningstar.com/news/pr-newswire/20250826io59019/bioarctic-and-novartis-sign-an-option-collaboration-and-license-agreement-using-braintransporter-for-an-upfront-payment-of-usd-30-million-plus-additional-potential-milestones-and-royalties
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet